2 results
Approved WMOCompleted
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
Approved WMORecruiting
The aims of this study are to build a database of oral microcirculation data from healthy volunteers between the ages of 18-67 and to compare the datasets between three age groups (18-20, 21-35, 35-67) and gender. An atlas of the microvascular…